Evidence map›Paper›PMID 37762485›Full record

ArticleInternational journal of molecular sciences2023

Differential Sensitivity of Germline and Somatic

Julie A Vendrell, Iulian O Ban, Isabelle Solassol, Patricia Audran, Simon Cabello-Aguilar, Delphine Topart, Clothilde Lindet-Bourgeois, Pierre-Emmanuel Colombo, Eric Legouffe, Véronique D'Hondt and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Julie A VendrellLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
Iulian O BanLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.ORCID 0009-0005-1213-2670
Isabelle SolassolUnité de Recherche Translationnelle, Institut Régional du Cancer de Montpellier (ICM), 34090 Montpellier, France.
Patricia AudranDépartement d'Anatomo-Pathologie, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France.
Simon Cabello-AguilarLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
Delphine TopartOncologie Médicale, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
Clothilde Lindet-BourgeoisOncologie Médicale, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
Pierre-Emmanuel ColomboDépartement de Chirurgie Oncologique, Institut Régional du Cancer de Montpellier (ICM), 34090 Montpellier, France.ORCID 0000-0002-0697-109X
Eric LegouffeOncologie Médicale, Institut de Cancérologie du Gard, 30900 Nîmes, France.
Véronique D'HondtDépartement d'Oncologie Médicale, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France.ORCID 0000-0001-5238-4032
Michel FabbroDépartement d'Oncologie Médicale, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France.ORCID 0000-0003-1910-4777
Jérôme SolassolLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.ORCID 0000-0002-0293-6158
Université de Montpellier · FRInstitut de Recherche en Cancérologie de Montpellier · FRInserm · FRInstitut de Cancérologie de Bourgogne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of

methodsA total of 805 HGSOC samples underwent

resultsIn our cohort, 13.2% of the HGSOC samples harbored a pathogenic

conclusionThe determination of the inheritance or acquisition of

Indexed as

Antineoplastic AgentsOvarian NeoplasmsClinical RelevanceFemaleGerm CellsHumansPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsBRCA1 and BRCA2 alterationgermline and somatic variantovarian cancerPARP inhibitor

Identifiers

PMID37762485
PMCPMC10532320
OpenAlexW4386814726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.